Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-12-01 Sale |
2022-12-02 5:00 pm |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
865 | $22.95 | $19,852 | 6,629 (Direct) |
View |
| 2022-11-29 Sale |
2022-12-01 5:00 pm |
Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer |
554 | $22.1 | $12,243 | 7,811 (Direct) |
View |
| 2022-11-04 Sale |
2022-11-08 5:51 pm |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
48,583 | $31.14 | $1,512,806 | 4,308,630 (Indirect) |
View |
| 2022-11-04 Sale |
2022-11-08 5:04 pm |
Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group |
97,166 | $31.14 | $3,025,611 | 4,308,630 (Indirect) |
View |
| 2022-11-02 Sale |
2022-11-04 5:58 pm |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
78,220 | $33.95 | $2,655,330 | 4,386,850 (Indirect) |
View |
| 2022-11-02 Sale |
2022-11-04 4:16 pm |
Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group |
156,440 | $33.95 | $5,310,658 | 4,386,850 (Indirect) |
View |
| 2022-10-31 Sale |
2022-11-02 9:02 pm |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
85,659 | $37.95 | $3,250,496 | 4,472,510 (Indirect) |
View |
| 2022-10-31 Sale |
2022-11-02 4:25 pm |
Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group |
171,319 | $37.95 | $6,501,031 | 4,472,510 (Indirect) |
View |
| 2022-10-28 Sale |
2022-11-01 5:00 pm |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
10,000 | $39.9 | $399,000 | 93,624 (Direct) |
View |
| 2022-10-03 Sale |
2022-10-05 5:00 pm |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $33.65 | $1,682,622 | 778,828 (Indirect Direct) |
View |
| 2022-09-23 Sale |
2022-09-27 5:00 pm |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
60,000 | $35.34 | $2,120,392 | 126,822 (Direct) |
View |
| 2022-08-10 Sale |
2022-08-11 5:00 pm |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $29.9 | $1,495,000 | 807,258 (Indirect Direct) |
View |
| 2022-07-20 Sale |
2022-07-22 5:00 pm |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
20,000 | $34.9 | $698,000 | 8,228 (Direct) |
View |
| 2022-07-19 Sale |
2022-07-21 5:00 pm |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $29.9 | $1,495,000 | 857,258 (Indirect Direct) |
View |
| 2022-07-13 Sale |
2022-07-15 5:00 pm |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
10,000 | $24.9 | $249,000 | 143,624 (Direct) |
View |
| 2022-07-12 Sale |
2022-07-14 5:24 pm |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 10% Owner |
163,000 | $20.78 | $3,386,520 | 570,729 (Indirect) |
View |
| 2022-07-01 Sale |
2022-07-06 12:56 pm |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 10% Owner |
38,775 | $15.66 | $607,217 | 773,729 (Indirect) |
View |
| 2022-06-29 Sale |
2022-07-01 2:54 pm |
Verve Therapeutics Inc. | VERV | FMR LLC See Remark 1 10% Owner |
53,219 | $15.45 | $822,476 | 772,504 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-09-18 Option Award |
2023-09-19 5:05 pm |
N/A 2033-09-17 |
Verve Therapeutics Inc. | VERV | Fiedorek Fred T. Chief Medical Officer |
180,000 | $0 | 180,000 (Direct) |
View |
| 2023-06-15 Option Award |
2023-06-20 5:00 pm |
N/A 2033-06-14 |
Verve Therapeutics Inc. | VERV | MacLean Michael F Director |
26,642 | $0 | 26,642 (Direct) |
View |
| 2023-06-15 Option Award |
2023-06-20 5:00 pm |
N/A 2033-06-14 |
Verve Therapeutics Inc. | VERV | Cumbo Alexander Director |
26,642 | $0 | 26,642 (Direct) |
View |
| 2023-06-15 Option Award |
2023-06-20 5:00 pm |
N/A 2033-06-14 |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
26,642 | $0 | 26,642 (Direct) |
View |
| 2023-06-15 Option Award |
2023-06-20 5:00 pm |
N/A 2033-06-14 |
Verve Therapeutics Inc. | VERV | ADELMAN BURT A Director |
26,642 | $0 | 26,642 (Direct) |
View |
| 2023-06-15 Option Award |
2023-06-20 5:00 pm |
N/A 2033-06-14 |
Verve Therapeutics Inc. | VERV | COATS LONNEL Director |
26,642 | $0 | 26,642 (Direct) |
View |
| 2023-06-15 Option Award |
2023-06-20 5:00 pm |
N/A 2033-06-14 |
Verve Therapeutics Inc. | VERV | Mikhail Sheila Director |
26,642 | $0 | 26,642 (Direct) |
View |
Ownership |
2023-02-23 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Nickerson Joan Chief Administrative Officer |
0 | $0 | 242,940 (Direct) |
View |
| 2023-02-14 Option Award |
2023-02-16 5:00 pm |
N/A 2033-02-13 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
182,800 | $0 | 182,800 (Direct) |
View |
| 2023-02-14 Option Award |
2023-02-16 5:00 pm |
N/A 2033-02-13 |
Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer |
182,800 | $0 | 182,800 (Direct) |
View |
| 2023-02-14 Option Award |
2023-02-16 5:00 pm |
N/A 2033-02-13 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
550,200 | $0 | 550,200 (Direct) |
View |
| 2023-02-14 Option Award |
2023-02-16 5:00 pm |
N/A 2033-02-13 |
Verve Therapeutics Inc. | VERV | MacLean Michael F Director |
7,000 | $0 | 7,000 (Direct) |
View |
| 2023-02-14 Option Award |
2023-02-16 5:00 pm |
N/A 2033-02-13 |
Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks |
182,800 | $0 | 182,800 (Direct) |
View |
| 2022-12-14 Exercise |
2022-12-16 5:00 pm |
N/A 2030-09-15 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
36,000 | $0 | 222,623 (Direct) |
View |
| 2022-12-14 Exercise |
2022-12-16 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
36,000 | $2.87 | 222,623 (Direct) |
View |
| 2022-11-29 Exercise |
2022-12-01 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer |
1,875 | $0 | 7,811 (Direct) |
View |
| 2022-11-04 Other |
2022-11-08 5:51 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
48,583 | $0 | 4,308,630 (Indirect) |
View |
| 2022-11-04 Other |
2022-11-08 5:04 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group |
48,583 | $0 | 4,308,630 (Indirect) |
View |
| 2022-11-02 Other |
2022-11-04 5:58 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
78,220 | $0 | 4,386,850 (Indirect) |
View |
| 2022-11-02 Other |
2022-11-04 4:16 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group |
78,220 | $0 | 4,386,850 (Indirect) |
View |
| 2022-10-31 Other |
2022-11-02 9:02 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
85,660 | $0 | 4,472,510 (Indirect) |
View |
| 2022-10-31 Other |
2022-11-02 4:25 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group |
85,660 | $0 | 4,472,510 (Indirect) |
View |
| 2022-10-28 Exercise |
2022-11-01 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
10,000 | $1.48 | 93,624 (Direct) |
View |
| 2022-10-28 Exercise |
2022-11-01 5:00 pm |
N/A 2029-09-16 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
10,000 | $0 | 93,624 (Direct) |
View |
| 2022-10-03 Exercise |
2022-10-05 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $1.39 | 778,828 (Direct) |
View |
| 2022-10-03 Exercise |
2022-10-05 5:00 pm |
N/A 2029-04-14 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $0 | 778,828 (Direct) |
View |
| 2022-09-23 Exercise |
2022-09-27 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
60,000 | $1.48 | 126,822 (Direct) |
View |
| 2022-09-23 Exercise |
2022-09-27 5:00 pm |
N/A 2029-09-16 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
60,000 | $0 | 126,822 (Direct) |
View |
| 2022-08-25 Exercise |
2022-08-29 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks |
33,749 | $1.48 | 446,786 (Direct) |
View |
| 2022-08-25 Exercise |
2022-08-29 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks |
51,203 | $1.39 | 446,786 (Direct) |
View |
| 2022-08-25 Exercise |
2022-08-29 5:00 pm |
N/A 2028-11-07 |
Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks |
95,787 | $0 | 446,786 (Direct) |
View |
| 2022-08-25 Exercise |
2022-08-29 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks |
10,835 | $2.87 | 446,786 (Direct) |
View |
| 2022-08-10 Exercise |
2022-08-11 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $1.39 | 807,258 (Direct) |
View |
| 2022-08-10 Exercise |
2022-08-11 5:00 pm |
N/A 2029-04-14 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $0 | 807,258 (Direct) |
View |
| 2022-08-08 Option Award |
2022-08-09 5:05 pm |
N/A 2032-08-07 |
Verve Therapeutics Inc. | VERV | COATS LONNEL Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2022-07-20 Exercise |
2022-07-22 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
20,000 | $1.39 | 8,228 (Direct) |
View |
| 2022-07-20 Exercise |
2022-07-22 5:00 pm |
N/A 2029-06-24 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
20,000 | $0 | 8,228 (Direct) |
View |
| 2022-07-19 Exercise |
2022-07-21 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $1.39 | 857,258 (Direct) |
View |
| 2022-07-19 Exercise |
2022-07-21 5:00 pm |
N/A 2029-04-14 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
50,000 | $0 | 857,258 (Direct) |
View |
| 2022-07-12 Gift |
2022-07-15 5:00 pm |
N/A 2031-02-11 |
Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer |
760,000 | $0 | 1,817,129 (Direct) |
View |
| 2022-07-13 Exercise |
2022-07-15 5:00 pm |
N/A N/A |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
10,000 | $1.48 | 143,624 (Direct) |
View |
| 2022-07-13 Exercise |
2022-07-15 5:00 pm |
N/A 2029-09-16 |
Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO |
10,000 | $0 | 143,624 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 5:01 pm |
N/A 2032-06-08 |
Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 5:00 pm |
N/A 2032-06-08 |
Verve Therapeutics Inc. | VERV | Cumbo Alexander Director |
31,000 | $0 | 31,000 (Direct) |
View |